Skip to main content
SpringerLink
Log in
Book cover

HIV and Liver Disease pp 9–13Cite as

Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons

  • Chapter
  • First Online:

Abstract

In the era of combination antiretroviral therapy (CART) and improved survival [1], liver disease has become a leading cause of morbidity and mortality among HIV-infected persons [2–4]. The term “liver disease” encompasses a wide spectrum, ranging from asymptomatic mild elevations of liver enzymes (aspartate aminotransferase, AST; alanine aminotransferase, ALT; alkaline phosphatase, ALP) to cirrhosis and end stage liver disease with all its complications (e.g., ascites, esophageal varices, hepatic encephalopathy).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–60.

    Article  PubMed  Google Scholar 

  2. Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.

    Article  PubMed  CAS  Google Scholar 

  3. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999. HIV Med. 2002;3(3):195–9.

    Article  PubMed  CAS  Google Scholar 

  4. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005;6(2):99–106.

    Article  PubMed  CAS  Google Scholar 

  5. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet. 1997;350(9089):1425–31.

    Article  PubMed  CAS  Google Scholar 

  6. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–7.

    Article  PubMed  CAS  Google Scholar 

  7. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632–41.

    Article  PubMed  Google Scholar 

  8. Rosenthal E, Salmon-Ceron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med. 2009;10(5):282–9.

    Article  PubMed  CAS  Google Scholar 

  9. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis. 2010;50(4):502–11.

    Article  PubMed  CAS  Google Scholar 

  10. Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci. 2008;53(5):1375–82.

    Article  PubMed  CAS  Google Scholar 

  11. Vergara S, Macias J, Mira JA, et al. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients. J Antimicrob Chemother. 2007;59(1):87–91.

    Article  PubMed  CAS  Google Scholar 

  12. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15(3):165–72.

    PubMed  CAS  Google Scholar 

  13. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182–9.

    Article  PubMed  CAS  Google Scholar 

  14. Puoti M, Nasta P, Gatti F, et al. HIV-related liver disease: ARV drugs, coinfection, and other risk factors. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8(1):30–42.

    Article  Google Scholar 

  15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80.

    Article  PubMed  CAS  Google Scholar 

  16. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38 Suppl 2:S90–7.

    Article  PubMed  CAS  Google Scholar 

  17. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6):831–7.

    Article  PubMed  Google Scholar 

  18. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS. 2005;19 Suppl 3:S99–S105.

    Article  PubMed  Google Scholar 

  19. Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996–2007. J Acquir Immune Defic Syndr. 2010;53(3):388–96.

    Article  PubMed  Google Scholar 

  20. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–14.

    PubMed  Google Scholar 

  21. Vogel M, Rockstroh JK. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS. 2009;4(3):171–5.

    Article  PubMed  Google Scholar 

  22. Benhamou Y, Bochet M, Martino VD, et al. Liver fibrosis progression in human immunnodeficiency virus and Hepatitis C virus coinfected patients. Hepatology. 1999;30:1054–8.

    Article  PubMed  CAS  Google Scholar 

  23. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet. 2000;356:1800–5.

    Article  PubMed  CAS  Google Scholar 

  24. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med. 2002;162(18):2125–32.

    Article  PubMed  Google Scholar 

  25. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with Human Immunodeficiency virus and progression to AIDS. J Infect Dis. 1995;172:1503–8.

    Article  PubMed  CAS  Google Scholar 

  26. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA. 2002;288(2):199–206.

    Article  PubMed  Google Scholar 

  27. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188(4):571–7.

    Article  PubMed  Google Scholar 

  28. Chun HM, Fieberg AM, Hullsiek KH, et al. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50(3):426–36.

    Article  PubMed  Google Scholar 

  29. Lo Re III V Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):315–20.

    Article  Google Scholar 

  30. Sanchez-Conde M, Berenguer J, Miralles P, et al. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin Infect Dis. 2006;43(5):640–4.

    Article  PubMed  Google Scholar 

  31. Sherman KE, Andersen J, Butt AA, Umbleja T, Alston B, Koziel MJ, Peters MG, Sulkowski M, Goodman ZD, Chung RT; for the Aids Clinical Trials Group A5178 Study Team. Sustained Long-term Antiviral Maintenance Therapy in HCV/HIV Coinfected Patients (SLAM-C). J Acquir Immune Defic Syndr 2010; October 1, Epub ahead of publication.

    Google Scholar 

  32. Kraemer KL, McGinnis KA, Skanderson M, et al. Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care. 2006;44(8 Suppl 2):S44–51.

    Article  PubMed  Google Scholar 

  33. Chaudhry AA, Sulkowski MS, Chander G, Moore RD. Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med. 2009;10(3):133–42.

    Article  PubMed  CAS  Google Scholar 

  34. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–19.

    Article  PubMed  Google Scholar 

  35. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9.

    Article  PubMed  CAS  Google Scholar 

  36. Williams R. Global challenges in liver disease. Hepatology. 2006;44(3):521–6.

    Article  PubMed  Google Scholar 

  37. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.

    Article  PubMed  Google Scholar 

  38. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.

    Article  PubMed  CAS  Google Scholar 

  39. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82.

    Article  PubMed  Google Scholar 

  40. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960–7.

    Article  PubMed  CAS  Google Scholar 

  41. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(3 Suppl 1):S17–29.

    PubMed  CAS  Google Scholar 

  42. Adams LA, Lymp JF, St SJ, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.

    Article  PubMed  Google Scholar 

  43. Hadigan C, Liebau J, Andersen R, Holalkere NS, Sahani DV. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr. 2007;46(3):312–7.

    Article  PubMed  Google Scholar 

  44. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47(2):250–7.

    Article  PubMed  Google Scholar 

  45. Mohammed SS, Aghdassi E, Salit IE, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr. 2007;45(4):432–8.

    Article  PubMed  CAS  Google Scholar 

  46. Loulergue P, Callard P, Bonnard P, Pialoux G. Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45(3):365.

    PubMed  Google Scholar 

  47. Castera L, Loko MA, Le BB, et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther. 2007;26(11–12):1489–98.

    Article  PubMed  CAS  Google Scholar 

  48. Neau D, Winnock M, Castera L, et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr. 2007;45(2):168–73.

    Article  PubMed  Google Scholar 

  49. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43(3):365–72.

    Article  PubMed  CAS  Google Scholar 

  50. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44(6):1026–32.

    Article  PubMed  CAS  Google Scholar 

  51. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis. 2005;192(11):1943–9.

    Article  PubMed  Google Scholar 

  52. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19(6):585–92.

    Article  PubMed  Google Scholar 

  53. Bani-sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS. 2006;20(4):525–31.

    Article  PubMed  Google Scholar 

  54. Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005;42(2):310–6.

    Article  PubMed  Google Scholar 

  55. El Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35(5 Suppl 2):S72–8.

    Article  PubMed  Google Scholar 

  56. McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24(31):5005–9.

    Article  PubMed  Google Scholar 

  57. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepatol. 2009;50(4):736–45.

    Article  PubMed  Google Scholar 

  58. Dinh MH, Stosor V, Rao SM, Miller FH, Green RM. Cryptogenic liver disease in HIV-seropositive men. HIV Med. 2009;10(7):447–53.

    Article  PubMed  CAS  Google Scholar 

  59. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21(2):187–92.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine/Division of Infectious Diseases, University of Pittsburgh, 3601 Fifth Ave, Ste 3A, Pittsburg, PA, 15213, USA

    Adeel A. Butt MD, MS

Authors
  1. Adeel A. Butt MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adeel A. Butt MD, MS .

Editor information

Editors and Affiliations

  1. College of Medicine, Dept. Internal Medicine, University of Cincinnati, Albert Sabin Way 231, Cincinnati, 45267-0560, Ohio, USA

    Kenneth E. Sherman

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Butt, A.A. (2012). Epidemiology of Liver Disease in Human Immunodeficiency Virus-Infected Persons. In: Sherman, K. (eds) HIV and Liver Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1712-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1712-6_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1711-9

  • Online ISBN: 978-1-4419-1712-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation